ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03426111
Previous Study | Return to List | Next Study

Multicenter, Randomized, Controlled and Double-blind Study of Efficacy and Safety of Endoscopic Gastric Tubulization in Patients With Non-alcoholic Steatohepatitis (NASH-APOLLO). (NASH-APOLLO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03426111
Recruitment Status : Recruiting
First Posted : February 8, 2018
Last Update Posted : December 12, 2018
Sponsor:
Collaborators:
Hospital Universitario Ramon y Cajal
Hospital Universitario Marqués de Valdecilla
Hospitales Universitarios Virgen del Rocío
Information provided by (Responsible Party):
Jose Luis Calleja, Puerta de Hierro University Hospital

Brief Summary:

Nonalcoholic steatohepatitis is a growing public health problem affecting over 5% of the population. These patients are at increased risk of cardiovascular and liver-related death and have higher rates of malignancy.

The currently standard of care is weight loss and physical exercise, with histological and analytical improvement in patients achieving a 5-10% reduction in body weight. However, less than 25% of the subjects achieve this goal. In obese patients , restrictive surgical treatments and gastric bypass have been successful in improving the metabolic syndrome, insulin resistance and liver histology.

Currently, less invasive and less costly endoscopic techniques are being developed. These techniques also achieve a gastric restriction with similar results than bariatric surgery. One of these is the OverStitch® system (Apollo Endosurgery, Austin, TX, USA). Our aim is to evaluate the efficacy and safety of this method in the improvement of liver histology in obese patients with nonalcoholic steatohepatitis.


Condition or disease Intervention/treatment Phase
Non-Alcoholic Fatty Liver Disease Obesity Device: Endoscopic Gastric Tubulization with OverStitch® system (Apollo Endosurgery, Austin, TX, USA) Behavioral: Lifestyle modification Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Multicenter, randomized,controlled and double-blind study with two parallel arms, placebo (normal endoscopy and lifestyle modification) or endoscopic gastric tubulization with OverStitch® system (Apollo Endosurgery, Austin, TX, USA) and lifestyle modification.
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Multicenter, Randomized, Controlled and Double-blind Study of Efficacy and Safety of Endoscopic Gastric Tubulization in Patients With Non-alcoholic Steatohepatitis (NASH-APOLLO).
Actual Study Start Date : April 18, 2018
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Endoscopy

Arm Intervention/treatment
Placebo Comparator: Placebo
Diagnostic upper endoscopy plus lifestyle modification.
Behavioral: Lifestyle modification
Hypocaloric diet and moderate physical exercise

Active Comparator: Treatment
Endoscopic gastric tubulization with OverStitch® system (Apollo Endosurgery, Austin, TX, USA) plus lifestyle modification.
Device: Endoscopic Gastric Tubulization with OverStitch® system (Apollo Endosurgery, Austin, TX, USA)
This endoscopic technique is defined as a gastric restriction by means of sutures of the entire gastric wall, transmurally, in order to simulate a gastric sleeve, in the same way as sleeve gastrectomy surgery. Gastroplasty is performed using an endoscopic suture system (OverStitch, Apollo Endosurgery Inc., Austin, Texas, USA) inserted into a dual-channel endoscope (GIF-2T160, Olympus Medical Systems Corp., Tokyo, Japan).

Behavioral: Lifestyle modification
Hypocaloric diet and moderate physical exercise




Primary Outcome Measures :
  1. To evaluate the efficacy of gastric tubulization + modification in lifestyle for 72 weeks compared to standard treatment / placebo in the resolution of NASH without worsening of fibrosis. [ Time Frame: 72 weeks ]
    NASH resolution is defined as the disappearance of ballooning and the disappearance or persistence of minimal lobular inflammation (grade 0 or 1) The worsening of fibrosis is defined as the progression of at least one stage.


Secondary Outcome Measures :
  1. Number of patients with improvement of fibrosis according to the CRN score NASH. [ Time Frame: 72 weeks ]
    to evaluate other histological changes after 72 weeks of treatment (CRN)

  2. Non alcoholic fatty liver disease (NASH) activity score (NAS). [ Time Frame: 72 weeks ]
    Number of patients with improvement in histological scores CRN score on NASH (NAS)

  3. steatosis-activity-fibrosis index score (steatosis activity fibrosis, SAF). [ Time Frame: 72 weeks ]
    Number of patients with improvement in the SAF score.

  4. Cardiovascular and death events related to the liver [ Time Frame: 72 weeks ]
    To evaluate the CV events in patients treated with gastric endoscopic tubulization + lifestyle modification with respect to lifestyle modification / placebo

  5. Changes in liver enzymes [ Time Frame: 72 weeks ]
    To evaluate liver enzymes in patients treated with gastric endoscopic tubulization + lifestyle modification with respect to lifestyle modification / placebo

  6. Changes in the noninvasive markers of fibrosis and steatosis [ Time Frame: 72 weeks ]
    To evaluate the noninvasive markers in patients treated with gastric endoscopic tubulization + lifestyle modification with respect to lifestyle modification / placebo

  7. Changes in lipid parameters [ Time Frame: 72 weeks ]
    To evaluate the lipid parameters in patients treated with gastric endoscopic tubulization + lifestyle modification with respect to lifestyle modification / placebo

  8. Variation in body weight [ Time Frame: 72 weeks ]
    To evaluate body weight in patients treated with gastric endoscopic tubulization + lifestyle modification with respect to lifestyle modification / placebo

  9. Biomarkers of endothelial and macrophage dysfunction [ Time Frame: 72 weeks ]
    To evaluate macrophage function in patients treated with gastric endoscopic tubulization + lifestyle modification with respect to lifestyle modification / placebo

  10. Changes in markers of homeostasis of glucose and insulin resistance [ Time Frame: 72 weeks ]
    To evaluate the glucose metabolism in patients treated with gastric endoscopic tubulization + lifestyle modification with respect to lifestyle modification / placebo

  11. Changes in cardiovascular risk profile [ Time Frame: 72 weeks ]
    To evaluate cardiovascular risk profile in patients treated with gastric endoscopic tubulization + lifestyle modification with respect to lifestyle modification / placebo

  12. Changes in quality of life (abbreviated health questionnaire SF-36). [ Time Frame: 72 weeks ]
    To evaluate the following endpoints in patients treated with gastric endoscopic tubulization + lifestyle modification with respect to lifestyle modification / placebo



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Men or women aged between 18 and 75 years (inclusive) at the time of the first screening visit.
  2. They must provide signed written informed consent and agree to comply the study protocol
  3. Body mass index> 30 kg / m².
  4. Histological confirmation of steatohepatitis in a diagnostic liver biopsy (biopsy obtained in the 6 months prior to randomization or during the selection period) with at least a score of 1 in each component of the NAS score (steatosis with a score of 0 to 3, degeneration by ballooning with a score of 0 to 2 and lobular inflammation with a score of 0 to 3) and fibrosis of 0 to <4, according to the staging system of CRN fibrosis on NASH.
  5. NAS score ≥ 4.
  6. For patients without fibrosis or with stage 1 fibrosis, the NAS score≥5 and one of the following conditions (metabolic syndrome (definition NCEP ATP III), DM type II, HOMA-IR> 6).
  7. The liver biopsy should have been done with a 16 G trucut needle and the minimum size should be 25 mm.

Exclusion Criteria:

  1. Known heart failure (Grade I to IV of the classification of the New York Heart Association).
  2. History of effective bariatric surgery in the 5 years prior to selection.
  3. Patients with a history of clinically significant acute cardiac event in the 6 months prior to selection, such as: acute cardiovascular event, cerebrovascular accident, transient ischemic attack, or coronary heart disease (angina pectoris, myocardial infarction, revascularization procedures).
  4. Weight loss of more than 5% in the 6 months prior to randomization.
  5. Liver cirrhosis.
  6. Non-cirrhotic portal hypertension.
  7. Recent or current background of significant consumption of alcoholic beverages (<5 years). In the case of men, significant consumption is usually defined as more than 30 g of pure alcohol per day. In the case of women, it is usually defined as more than 20 g of pure alcohol per day.
  8. Esophagogastric varices.
  9. Hepatocellular carcinoma
  10. Portal thrombosis.
  11. Pregnancy.
  12. Refusal to give informed consent.
  13. Any medical condition that could reduce life expectancy to less than 2 years, including known cancers.
  14. Signs of any other unstable or clinically significant immunological, endocrine, hematological, gastrointestinal, neurological, neoplastic or psychiatric disease without treatment.
  15. Instability or mental incompetence, so that the validity of the informed consent or the ability to comply with the study are uncertain.

    In addition to the above criteria, the patient must not present any of the following biological exclusion criteria:

  16. Antibodies positive for the human immunodeficiency virus.
  17. Aspartate aminotransferase (AST) and / or ALT> 10 x upper limit of normal (ULN).
  18. Total bilirubin> 25 μmol / l (1.5 mg / dl).
  19. Standardized international index> 1.4.
  20. Platelet count <100 000 / mm3.
  21. Serum creatinine levels> 135 μmol / l (> 1.53 mg / dl) in men and> 110 μmol / l (> 1.24 mg / dl) in women.
  22. Significant renal disease, including nephritic syndrome, chronic kidney disease (patients with markers of hepatic injury or estimated glomerular filtration rate [eGFR] of less than 60 ml / min / 1.73 m2). If an abnormal value is obtained at the first screening visit, the eGFR measurement may be repeated before randomization within the following time frame: minimum 4 weeks after the initial test and maximum 2 weeks before the expected randomization. An abnormal repeated eGFR (less than 60 ml / min / 1.73 m2) leads to exclusion from the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03426111


Contacts
Contact: Jose Luis Calleja, Prof +34911916000 ext 417175 joseluis.calleja@uam.es
Contact: Javier Abad, MD +34650814289 jabad@salud.madrid.org

Locations
Spain
Jose Luis Calleja Recruiting
Majadahonda, Madrid, Spain, 28222
Contact: Jose Luis Calleja, Prof    +34911916000 ext 417175    joseluis.calleja@uam.es   
Contact: Javier Abad, MD    +34650814289    jabad@salud.madrid.org   
Principal Investigator: Jose Luis Calleja, Prof         
Sub-Investigator: Elba Llop, PhD         
Sub-Investigator: Jose Luis Martinez, PhD         
Sub-Investigator: Marta Hernandez, MD         
Sub-Investigator: Javier Abad, MD         
Sponsors and Collaborators
Puerta de Hierro University Hospital
Hospital Universitario Ramon y Cajal
Hospital Universitario Marqués de Valdecilla
Hospitales Universitarios Virgen del Rocío

Additional Information:
Publications:

Responsible Party: Jose Luis Calleja, Professor and Head of Hepatology Unit of Puerta de Hierro University Hospital, Puerta de Hierro University Hospital
ClinicalTrials.gov Identifier: NCT03426111     History of Changes
Other Study ID Numbers: PI17-00499
First Posted: February 8, 2018    Key Record Dates
Last Update Posted: December 12, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Jose Luis Calleja, Puerta de Hierro University Hospital:
Non-Alcoholic Fatty Liver Disease
NASH
Obesity
Endoscopic gastric tubulization
Non-alcoholic steatohepatitis

Additional relevant MeSH terms:
Liver Diseases
Fatty Liver
Non-alcoholic Fatty Liver Disease
Digestive System Diseases